TrialThe Lancet. Oncology2019

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Cathy Eng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.